JP2023533485A - 重症型の肺高血圧症の治療方法 - Google Patents

重症型の肺高血圧症の治療方法 Download PDF

Info

Publication number
JP2023533485A
JP2023533485A JP2022580425A JP2022580425A JP2023533485A JP 2023533485 A JP2023533485 A JP 2023533485A JP 2022580425 A JP2022580425 A JP 2022580425A JP 2022580425 A JP2022580425 A JP 2022580425A JP 2023533485 A JP2023533485 A JP 2023533485A
Authority
JP
Japan
Prior art keywords
copper
pah
ttm
tetrathiomolybdate
copper chelator
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580425A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023533485A5 (https=
Inventor
ノーバート， エフ． ヴォルケル，
チャールズ マゴルスク，
Original Assignee
リバースパ エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リバースパ エルエルシー filed Critical リバースパ エルエルシー
Publication of JP2023533485A publication Critical patent/JP2023533485A/ja
Publication of JP2023533485A5 publication Critical patent/JP2023533485A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/02—Ammonia; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2022580425A 2019-06-26 2021-08-24 重症型の肺高血圧症の治療方法 Pending JP2023533485A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962866781P 2019-06-26 2019-06-26
PCT/US2021/047297 WO2021263250A2 (en) 2019-06-26 2021-08-24 Method of treating severe forms of pulmonary hypertension

Publications (2)

Publication Number Publication Date
JP2023533485A true JP2023533485A (ja) 2023-08-03
JP2023533485A5 JP2023533485A5 (https=) 2024-09-02

Family

ID=73891720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022580425A Pending JP2023533485A (ja) 2019-06-26 2021-08-24 重症型の肺高血圧症の治療方法

Country Status (4)

Country Link
US (1) US12268710B2 (https=)
JP (1) JP2023533485A (https=)
CN (1) CN112138024A (https=)
WO (1) WO2021263250A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112138024A (zh) * 2019-06-26 2020-12-29 里弗斯Pah有限责任公司 治疗严重形式的肺动脉高压的方法
GB2612210B (en) * 2020-06-24 2025-08-27 Reverspah Llc Pharmaceutical composition comprising a tetrathiomolybdate salt and a diethylcarbamazine
CN118524835A (zh) * 2021-11-10 2024-08-20 瑞沃斯帕有限责任公司 用于治疗癌症的方法和组合物
WO2023086873A1 (en) * 2021-11-10 2023-05-19 Reverspah Llc Methods and compositions for treating cancer
JP2025523707A (ja) * 2022-05-28 2025-07-23 アヴァリン ファーマ インク． ニンテダニブおよびニンテダニブの組み合わせ乾燥粉末組成物と使用
CN115737661A (zh) * 2022-10-24 2023-03-07 中国人民解放军海军军医大学第一附属医院 一种黄芩苷在制备抑制视网膜新生血管的药物中的应用
CN115624562B (zh) * 2022-12-02 2023-05-09 首都医科大学附属北京友谊医院 黄芩苷在制备治疗对免疫检查点抑制剂无应答/超进展的肿瘤的药物中的应用
CN118078999B (zh) * 2024-02-23 2025-03-18 中山大学附属第一医院 铜离子螯合剂联合NF-κB抑制剂在制备肿瘤治疗药物中的应用
CN120789268B (zh) * 2025-09-16 2025-12-05 中南大学 Aldh1a2抑制剂和检测aldh1a2或ra的试剂的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
US20190231815A1 (en) * 2015-07-28 2019-08-01 Insmed Incorporated Compositions comprising copper chelators and methods of use thereof for treating vasculopathies

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1649577A (zh) 2002-03-08 2005-08-03 普罗特米克斯公司 预防和/或治疗心血管疾病和/或相关的心衰
CA2675230A1 (en) * 2006-01-10 2008-07-26 Pipex, Inc. Pharmaceutical compositions and methods to achieve and maintain a targeted and stable copper status and prevent and treat copper-related central nervous system diseases
US20110287110A1 (en) * 2010-04-23 2011-11-24 Mark Wesley Dewhirst Combination cancer treatment
US10195164B2 (en) * 2015-05-13 2019-02-05 Duke University Use of disulfiram for inflammatory breast cancer therapy
CN106257609B (zh) 2016-08-22 2018-03-06 河南师范大学 一种制备单层1t相二硫化钼/石墨烯复合材料的方法
CN112138024A (zh) 2019-06-26 2020-12-29 里弗斯Pah有限责任公司 治疗严重形式的肺动脉高压的方法
WO2022035813A1 (en) * 2020-08-10 2022-02-17 Reverspah Llc Method and composition for treating corona virus, influenza, and acute respiratory distress syndrome
WO2023086873A1 (en) * 2021-11-10 2023-05-19 Reverspah Llc Methods and compositions for treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012122295A2 (en) * 2011-03-07 2012-09-13 Ned Biosystems, Inc. Treatment for pancreatic adenocarcinoma and other cancers of epithelial origin
US20190231815A1 (en) * 2015-07-28 2019-08-01 Insmed Incorporated Compositions comprising copper chelators and methods of use thereof for treating vasculopathies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 183, JPN6025029356, 2011, pages 3417, ISSN: 0005774773 *
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 46, JPN6025029355, 2012, pages 582 - 591, ISSN: 0005774772 *
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 21, no. 9, JPN6025029357, 2017, pages 1859 - 1869, ISSN: 0005774775 *
PLOS ONE, vol. 10, no. 3, JPN6025029359, 2015, pages 0120157, ISSN: 0005645840 *

Also Published As

Publication number Publication date
WO2021263250A2 (en) 2021-12-30
CN112138024A (zh) 2020-12-29
US12268710B2 (en) 2025-04-08
WO2021263250A3 (en) 2022-02-24
US20200405748A1 (en) 2020-12-31

Similar Documents

Publication Publication Date Title
JP2023533485A (ja) 重症型の肺高血圧症の治療方法
US20230092181A1 (en) Intermittent dosing of mdm2 inhibitor
KR102463617B1 (ko) Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법
US20100029683A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphateses
KR20130045341A (ko) 암 치료를 위한 저산소증 활성 프로드러그와 항혈관형성제의 투여
CN114246864B (zh) Csf1r激酶抑制剂及其用途
AU2020279003B2 (en) Oxathiazin compounds for inhibiting GAPDH
JP2018035112A (ja) 抗癌剤の抗腫瘍効果の増強剤、癌治療剤、及び癌治療用医薬組成物。
JP2019019082A (ja) 誤りがちｄｎａ修復経路の抑制によるがんの治療
HK40041555A (en) Method of treating severe forms of pulmonary hypertension
CN116173040B (zh) Xmd17109作为arih1激动剂的用途
US12472227B2 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
EP3854411A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
WO2026074499A1 (en) Methods and compositions for inhibiting c-myc
KR20190077998A (ko) Tpx-0005를 유효성분으로 포함하는 대장암 예방 또는 치료용 약학적 조성물
HK1231740B (en) Intermittent dosing of mdm2 inhibitor
HK1231740A1 (en) Intermittent dosing of mdm2 inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240823

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240823

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250714

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250722

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260417